title: Effect of hepatocyte growth-promoting factors on myocardial ischemia during exercise in patients with severe coronary artery disease.
abstract: Hepatocyte growth-promoting factor (pHGF) has the greatest potential as a therapeutic agent for vascular growth factor. The aim of this study was to investigate the effect of pHGF on myocardial ischemia and exercise capacity in patients with severe coronary artery disease (CAD). Forty-nine patients were enrolled for a two week treatment period. Treadmill graded exercise tests with gas analysis were conducted before and after therapy. Serum levels of HGF were significantly elevated after therapy. The degrees of exercise-induced ST segment depression were decreased more significantly in the pHGF group. Similar differences were also found in the maximum heart rate and the maximum heart rate when the ST segment was depressed 1 mm while undergoing the treadmill graded exercise test. Both were increased more significantly in the pHGF group. Total exercise time, systolic blood pressure in the peak of exercise, the length of time that ST segment depression of 1 mm is needed, and total work all were increased in both groups after intervention. Furthermore, total exercise time and total work were increased more significantly in the pHGF group. The levels of HGF increased significantly after pHGF treatment. pHGF could favorably improve exercise-induced myocardial ischemia and enhance exercise capacity in patients with severe CAD.
authors.affiliation: Department of Cardiology, the First People's Hospital of Hangzhou and Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou City, China.
authors.forename: Ningfu
authors.initials: N
authors.lastname: Wang
authors.forename: Guoxin
authors.initials: G
authors.lastname: Tong
authors.forename: Jianmin
authors.initials: J
authors.lastname: Yang
authors.forename: Zhanlin
authors.initials: Z
authors.lastname: Zhou
authors.forename: Hao
authors.initials: H
authors.lastname: Pan
authors.forename: Yong
authors.initials: Y
authors.lastname: Huo
authors.forename: Jian
authors.initials: J
authors.lastname: Xu
authors.forename: Xingwei
authors.initials: X
authors.lastname: Zhang
authors.forename: Feng
authors.initials: F
authors.lastname: Ling
authors.forename: Peizhang
authors.initials: P
authors.lastname: Li
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001794:Blood Pressure / Q000187:drug effects; D002317:Cardiovascular Agents / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D018618:Echocardiography, Doppler, Color; D004562:Electrocardiography / Q000187:drug effects*; D005080:Exercise Test / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D017228:Hepatocyte Growth Factor / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy*; D011446:Prospective Studies; D013318:Stroke Volume / Q000187:drug effects
chemical_list: D002317:Cardiovascular Agents; D017228:Hepatocyte Growth Factor